SUZHOU,

苏州，

China

中国

,

，

April 1, 2025

2025年4月1日

/PRNewswire/ -- Today, April 1st, Peijia Medical Technology (Suzhou) Co., Ltd. held a strategic innovation cooperation signing ceremony and a press conference to announce the research and development achievements of polymer heart valves using ultra-high molecular weight polyethylene (UHMWPE) and thermoplastic polyurethane (TPU) from the Biomedical business of dsm-firmenich, innovators in nutrition, health, and beauty, at Peijia Medical's global headquarters.

/PRNewswire/ -- 今天，4月1日，沛嘉医疗科技（苏州）有限公司举行了战略创新合作签约仪式和新闻发布会，宣布在营养、健康和美容领域创新者帝斯曼-芬美意的生物医学业务中，使用超高分子量聚乙烯（UHMWPE）和热塑性聚氨酯（TPU）研发的聚合物心脏瓣膜的研究成果，活动在沛嘉医疗全球总部举行。

The signing of the strategic innovation partnership agreement between the two parties will further focus on the research and development innovation of polymer heart valve materials, which is expected to initiate an epoch-making transformation in the field of high-end medical device materials worldwide..

双方签订战略合作创新伙伴关系协议，将进一步聚焦于高分子心脏瓣膜材料的研发创新，有望开启全球高端医疗器械材料领域的划时代变革。

Continue Reading

继续阅读

Peijia Medical is a leading enterprise in the field of high-end medical devices for structural heart disease and cerebrovascular intervention in

沛嘉医疗是结构性心脏病和脑血管介入高端医疗器械领域的领先企业。

China

中国

. It boasts a comprehensive portfolio of structural heart disease products and a product development team that covers major valvular diseases and next-generation core technologies, as well as a complete range of commercialized products and innovative procedural combinations for the hemorrhagic and ischemic stroke markets.

它拥有全面的结构性心脏病产品组合，以及涵盖主要瓣膜疾病和下一代核心技术的产品开发团队，还有针对出血性和缺血性卒中市场的完整商业化产品系列和创新手术组合。

In 2024, Peijia Medical's sales revenue .

2024年，沛嘉医疗的销售收入 。

615 million RMB

6亿1500万元人民币

, marking a year-on-year increase of approximately 40%.

，同比增长了约40%。

The Biomedical business of dsm-firmenich is headquartered in

dsm-firmenich的生物医学业务总部位于

Pennsylvania, USA

美国宾夕法尼亚州

, with offices and an Innovation & Application Center in

，设有办公室和创新应用中心在

the Netherlands

荷兰

and

和

Shanghai, China

中国上海

. As part of the dsm-firmenich group, Biomedical has unmatched expertise in biomaterials and their applications, helping partners such as Peijia create groundbreaking innovations for patients everywhere.

作为dsm-firmenich集团的一部分，Biomedical在生物材料及其应用方面拥有无与伦比的专业知识，帮助像Peijia这样的合作伙伴为全球患者创造突破性的创新。

In this collaboration, Peijia Medical and Biomedical have joined forces to achieve a new breakthrough in the research and development of ultra-high molecular weight polyethylene (UHMWPE) and thermoplastic polyurethane (TPU) heart valve materials. According to the agreement, the two parties will establish a long-term, stable, and mutually beneficial strategic innovation partnership.

在这次合作中，沛嘉医疗与生物医学公司携手，在超高分子量聚乙烯（UHMWPE）和热塑性聚氨酯（TPU）心脏瓣膜材料的研发上取得了新的突破。根据协议，双方将建立长期、稳定、互利的战略创新伙伴关系。

Using dsm-firmenich biomaterials, the respective R&D teams will collaborate on the design and development of new high-end medical device products, the optimization of key raw material properties, the research and development of new materials, as well as the development and application of advanced manufacturing processes and technologies, all based on UHMWPE materials..

使用帝斯曼-芬美意的生物材料，各自的研发团队将基于超高分子量聚乙烯材料，合作进行高端新型医疗设备产品设计与开发、关键原材料性能优化、新材料的研发，以及先进制造工艺和技术的开发与应用。

Ultra-high molecular weight polyethylene (UHMWPE) fiber is a lightweight and high-strength polymer material, boasting a strength 15 times that of steel structures of the same size. Utilizing ultra-fine fibers and through unique weaving and multi-layer fusion technologies, polymer valve materials can be produced, which can perfectly replace the existing animal-derived materials for heart valves.

超高分子量聚乙烯（UHMWPE）纤维是一种轻质高强度的高分子材料，其强度是同等尺寸钢结构的15倍。利用超细纤维，并通过独特的编织和多层融合技术，可以生产出聚合物瓣膜材料，能够完美替代现有的动物源性心脏瓣膜材料。

There is significant potential for advancement in the flexibility and biocompatibility of the product, enabling a revolutionary iterative upgrade of valve materials..

产品在柔韧性和生物相容性方面有显著的改进潜力，可实现瓣膜材料的革命性迭代升级。

Polymer valve materials are a type of non-biological, inorganic material with distinct advantages in physical and biochemical properties, as well as lifespan, and are also suitable for younger patients. Compared to traditional animal-derived valve materials, polymer valve materials offer two major advantages: on one hand, they enhance product longevity and broaden the range of indications; on the other hand, they reduce costs and are suitable for mass production.

聚合物瓣膜材料是一类非生物的无机材料，在物理和生化性能以及使用寿命方面均有显著优势，且适合较为年轻的患者。与传统的动物源性瓣膜材料相比，聚合物瓣膜材料具备两大优势：一方面延长了产品的使用寿命并拓宽了适应症范围；另一方面降低了成本，适合大规模生产。

This is of significant importance for the development of the heart valve market and for benefiting a larger patient population..

这对心脏瓣膜市场的发展和造福更广大的患者群体具有重要意义。

The polymer valve independently developed by Peijia Medical is a novel type of polymer valve that utilizes a five-layer bionic polymer fiber fabric as the valve material, simulating the functions of the corresponding layers of the human body's own valve leaflets, thus more closely approximating the various functions of the human body's own valves.

沛嘉医疗自主研发的聚合物瓣膜是一种新型的聚合物瓣膜，它采用五层仿生聚合物纤维织物作为瓣膜材料，模拟人体自身瓣叶相应层次的功能，从而更接近人体自身瓣膜的各种功能。

This product has demonstrated stable hemodynamics after 400 million cycles of accelerated fatigue testing, showcasing exceptional durability, with an expected lifespan far exceeding that of current biological source valve materials. The development of this product has been successfully selected as a key core technology research project in Suzhou's global 'unveiling and leading' initiative.

该产品经过4亿次加速疲劳试验，展现了稳定的血液动力学性能，表现出卓越的耐久性，预期寿命远远超过目前生物源瓣膜材料。该产品的研发成功入选苏州市全球“揭榜挂帅”重点项目核心技术攻关项目。

Currently, the product has completed animal testing and is preparing to enter clinical trials..

目前，该产品已完成动物试验，正准备进入临床试验阶段。

Pan Kongrong, Chief Operating Officer of Peijia Medical, stated that on the basis of years of collaboration with Biomedical, the two companies will now enter a deeper level of synergy. The development of polymer valve leaflet materials, as a core platform technology of Peijia Medical, once completed, will be applied across various product lines to enhance the performance of each product and unlock the application of ultra-high molecular weight polyethylene in the field of structural heart disease..

沛嘉医疗首席运营官潘孔荣表示，基于与Biomedical多年来的合作，两家公司将进入更深层次的协同阶段。聚合物瓣膜材料作为沛嘉医疗的核心平台技术，一旦开发成功，将横向应用到各个产品线，提升每一个产品的性能，从而打开超高分子量聚乙烯在结构性心脏病领域的应用。

Paul Spencer

保罗·斯宾塞

, President of the Biomedical division at dsm-firmenich, noted 'At dsm-firmenich, we are committed to advancing vascular care with innovative biomaterial solutions that support the goals of driving better clinical outcomes, reducing healthcare costs, and improving the lives of patients worldwide. We are very excited to formally collaborate with Peijia to bring progress to life in .

帝斯曼-芬美意生物医学部门总裁表示：“在帝斯曼-芬美意，我们致力于通过创新的生物材料解决方案推动血管护理的发展，助力实现更好的临床效果、降低医疗成本，并改善全球患者的生活质量。我们非常高兴能与佩佳正式合作，为生命带来进步。”

China

中国

.'

.'

SOURCE Peijia Medical

来源：沛嘉医疗

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用